8CB0 Stock Overview
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cannara Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.56 |
| 52 Week High | CA$0.75 |
| 52 Week Low | CA$0.49 |
| Beta | 1.15 |
| 1 Month Change | -8.13% |
| 3 Month Change | -5.83% |
| 1 Year Change | 6.60% |
| 3 Year Change | -40.84% |
| 5 Year Change | -48.17% |
| Change since IPO | -68.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8CB0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.6% | 3.9% | 2.0% |
| 1Y | 6.6% | -28.2% | 2.0% |
Return vs Industry: 8CB0 exceeded the German Pharmaceuticals industry which returned -28.6% over the past year.
Return vs Market: 8CB0 exceeded the German Market which returned 1.3% over the past year.
Price Volatility
| 8CB0 volatility | |
|---|---|
| 8CB0 Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8CB0 has not had significant price volatility in the past 3 months.
Volatility Over Time: 8CB0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Zohar Krivorot | cannara.ca |
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products. The company sells its products through wholesalers and online merchandisers.
Cannara Biotech Inc. Fundamentals Summary
| 8CB0 fundamental statistics | |
|---|---|
| Market cap | €52.34m |
| Earnings (TTM) | €6.19m |
| Revenue (TTM) | €45.44m |
8.4x
P/E Ratio1.1x
P/S RatioIs 8CB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8CB0 income statement (TTM) | |
|---|---|
| Revenue | CA$66.43m |
| Cost of Revenue | CA$35.80m |
| Gross Profit | CA$30.63m |
| Other Expenses | CA$21.58m |
| Earnings | CA$9.05m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 46.11% |
| Net Profit Margin | 13.62% |
| Debt/Equity Ratio | 58.5% |
How did 8CB0 perform over the long term?
See historical performance and comparison